Feasibility of Multi-platform, Multi-site Clinical Trials of Proton MRS
Petrus L, Ross B, Chen D
A major impediment to the acceptance and reimbursement of clinical MRS for diagnosis is the absence of clinical and societal efficacy, using the Thornbury and Fryback criteria of Evidence Based Medicine (EBM). Multi-site trials on 100s of patients are essential. A minimum requirement for multi-site MRS trials is comparability of results achieved across the many different MRS platforms available. As part of the effort to standardize MRS procedures we establish that two major vendors (Toshiba: Vantage 1.5T) and GE Healthcare: LX 1.5T) generate statistically indistinguishable MRS results in normal and in common brain pathologies.